1
STOPPING OPIOIDS
William Morrone, DO MS, FACOFP DABAM DAAPM Deputy Chief Medical Examiner & AOAAM
June 24, 2015Noon ET
2
William Morrone DO, Disclosures
• William Morrone, DO has presented numerous programs on Pain Management, Forensic and Addiction Medicine. Opinions of Dr Morrone are not the opinions of the Covenant Hospital, AOAAM, Queen of Angels Detox, Bay County Medical Examiner’s Office & Recovery Pathways. Dr Morrone has no conflicts to report.
• Dr Morrone does not endorse any product or organization.
• Dr Morrone is a associate clinical professor at Michigan State University and faculty at the Thumb Pain Education Center.
3
Target Audience
• The goal of PCSS-O is to offer evidence-based trainings on the safe and effective management of opioid medications in the treatment of pain and/or opioid use disorder (addiction or dependence).
• Our focus is to reach providers and/or providers-in-training from diverse healthcare professions including physicians, nurses, dentists, physician assistants, pharmacists, and program administrators.
4
Educational Objectives
• @ conclusion of this activity participants should be able to: Differentiate Naloxone Opportunities Interview - identify lack of benefit to patient Recognize 5 reasons to Stop Opioids Recognize 4 options to Stop Opioids Recognize 3 phases of Weaning
Temple Opioid - SSRN-id1437163 – Temple University Beasley School of Law
5
Stop death = Stop OPIOIDS on bad risk ratios/treatment goals not met
5
Understand when to appropriately refer high-risk patients to pain management and/or addiction specialists
6
FBI Annual deaths: US
72015 PCSS-O
8
92015 PCSS-O
10
Why are people still dying?
People die because provider education is slower or less effective than advocacy, FDA regulation & federal legislation
11
1212
1313
1414
152015 PCSS-O
16
How do we stop people dying?
• Naloxone Co-prescription to high risk groups
• Stop prescriptions of opioids to people with inappropriate risk benefit ratios
2015 PCSS-O
1717
1818
19
NIH Conclusions Sept 28-29 2014
Aberrant drug-related behaviors ranged from 5.7 percent to 37.1 %. Long-term opioid therapy was associated with increased risk of: • abuse (one cohort study), • overdose (one cohort study), • fracture (two observational studies), • myocardial infarction (two observationals)• sexual dysfunction (one cross-sectional study)several studies showing a dose-dependent association.
2015 PCSS-O
20
NIH Conclusions Sept 28-29 2014
• Evidence on long-term opioid therapy for chronic pain is very limited but suggests an increased risk of serious harms that appears to be dose-dependent.
• More research is needed to understand long-term benefits, risk of abuse and related outcomes, and effectiveness of different opioid prescribing methods and risk mitigation strategies.
2015 PCSS-O
21
Discontinuing Opioids
•Educate the patient about the need to stop when goals are not met.
• Discuss the process involved• Explain alternative therapies.
2015 PCSS-O
22
Painful Truth
• # 1.• NO STUDIES exist with Opioid versus nonOpioid for chronic pain outcomes 1 year or more
2015 PCSS-O
23
Painful Truth
• # 2.• 20-25 years of treatment based on opioid use versus placebo in chronic pain studies that lasted < 6 weeks
2015 PCSS-O
24
VA definitionDefinition of Chronic Pain:
CHRONIC PAIN (non-cancer pain) generally refers to intractable pain that exists for three or more months & does not resolve in response to treatment.
2015 PCSS-O
25
3 requirements to stop
• Initial patient assessment
• Trial of Opioid Therapy& Functional Goals
• Adequate Monitoring
2015 PCSS-O
26
Patient Reassessment = EXIT STATEGY
26
Adapted from Katz NP. Patient Level Opioid Risk Management. PainEDU.org Manual. 2007
Initial Patient Assessment
Trial of Opioid TherapyFunctional Goals
Patient Reassessment;Adapt the Tx Plan;
Intervene as Needed
Continue or Adjust or Rotate or D/C Opioids
Exit Strategy
Adequate Monitoring Consultation/Referral
27
Neither Safe nor Effective
• Whereas it was previously thought that unlimited dose escalation was safe, evidence now suggests that prolonged, high-dose opioid therapy may be neither safe nor effective.
•• (review) Ballantyne & Mao NEJM 349;20 2003
2015 PCSS-O
2828
29
OPIOID vs COX-2Coronary heart disease outcomes: chronic opioid & COX-2 users compared to a general population cohort Wendy Carman et al
Pharmacoepidemiology& Drug Safety Volume 20, Issue 7 pp 754-762 July 2011N = (145,657 opioid & 122,810 COX-2) 268,467
2015 PCSS-O
30
Opioid vs Cox-2 Incident Rate Ratio
2015 PCSS-O
0 0.5 1 1.5 2 2.5 3
low dose
high dose
cox-2
chronic OP
Series…Series…
31
Murphy et al (2013) Clin J Pain
• Opioid analgesic use at admission had no discernible impact on treatment outcome in this large VA sample with moderate to severe chronic pain syndrome.
• Bold clinical implications of these findings for long-term chronic pain treatment, in light of the risks associated with opioids.
2015 PCSS-O
32
Conditions Outside Discontinuationwhere treatment goals are not linked
• Post surgical• Acute trauma• Cancer Pain• End of Life pain• Pathoanatomic pain
2015 PCSS-O
3333
34
NIH-Opioids Poor Outcomes
3 cases where evidence suggests poor outcomes from opioids:
1. Low back pain w/no pathoanatomic basis
2. Fibromyalgia3. Headache
2015 PCSS-O
3535
362015 PCSS-O
3737
3838
39
Ask the patient to demonstrate progress
• Bring in family members to witness • Show a gym membership card & visits• Describe a regular exercise program• Show that they’re obtaining needed
support (group counseling – therapist)• New employment
2015 PCSS-O
40
Guidelines• Physicians are in a better position now to
control opioid use so that it helps, rather than harms, patients.
• Current guidelines recommend:• # 1.) a cautious approach to dose
escalation and• # 2.) the discontinuation of opioids
if treatment goals are not met.
2015 PCSS-O
41
Why to “not prescribe” for chronic lower back pain ??
• Alternate treatments (psycho & physical) have a stronger evidence base
• OPIOIDS are deactivating not activating
• Reduced prescribing for nonspecific back pain would reduce overall prescribing and benefit public health
Hill et al, Lancet 2011, 378
41
422015 PCSS-O
432015 PCSS-O
442015 PCSS-O
452015 PCSS-O
46
Myofascial Release
472015 PCSS-O
48
ADJUVANTS• Adjuvants allow opioids to be analgesic or give
greater analgesia at current/lower dose.• Gabapentin or Namenda or Amantadine• Valproic Acid or Phenytoin or Pregabalin• Amitriptyline or Ketamine or Benadryl• Promethazine or Dextromethorphan • Baclofen or Ranitidine or Clonidine• Carbamazepine 200-1600mg per day.
2015 PCSS-O
49
GUIDELINES need EXIT
• Physicians are in a better position now to control opioid use so that it helps, rather than harms, patients.
• Current guidelines recommend:• # 1.) a cautious approach to dose
escalation and• # 2.) the discontinuation of
opioids if treatment goals are not met.
49
50
GUIDELINES need EXIT
• Physicians are in a better position now to control opioid use so that it helps, rather than harms, patients.
• Corrected guidelines recommend:• # 1.) the discontinuation of
opioids if treatment goals are not met.
• # 2.) a cautious approach to dose escalation
50
51
FOUR (4) OPTIONS
• Refer - methadone clinic• 100 % buprenorphine
conversion (stone cold)• 3 to 10 month taper• Go find another provider
2015 PCSS-O
52
5 Reasons: Discontinuing Opioids
Chou R, et al. J Pain. 2009;10:113-30. Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain. 2010.
|
No progress toward therapeutic goals
Intolerable & Unmanageable AEs
• 1 or 2 episodes of increasing dose without prescriber knowledge
• Sharing medications• Unapproved opioid use to treat another
symptom (e.g., insomnia)
• Use of illicit drugs or unprescribedopioids
• Repeatedly obtaining opioids from multiple outside sources
• Prescription forgery• Multiple episodes of prescription
loss
Nonadherence or unsafe behavior
Aberrant behaviors suggest addiction &/or diversion
Pain level decreases in
stable patients
53
5 REASONS lead to 4 OPTIONS
• Explain why lack of progress or breach of treatment agreements raise your concerns of addiction.
• Benefits of opioids no longer outweigh risks.“I cannot responsibly and morally continue prescribing opioids, as I feel it would cause you more harm than good.”
• Always offer a referral for addiction treatment.
2015 PCSS-O
54
THREE (3) phases of weaning
• #1. Establish a baseline• #2. Reduce the dose• #3. Treat protracted / post-acute withdrawal
2015 PCSS-O
55
MEDICAL TAPER
1. Note in chart: legitimate pain diagnosis, reason for discontinuation of opioids, nonemergency situation, outline of taper, end date for prescribing
2. Have the patient read and initial the note.3. Prescribe 10% fewer opioid analgesics
per week
2015 PCSS-O
56
MEDICAL TAPER4. Reassess at week #8:
– If going well, continue– If not going well, plan for
detoxification5. On week #10:
• Stop prescribing, • educate patient about withdrawal
symptoms, • urge patient to go to the ER if withdrawal
appears, and admit for detoxification
2015 PCSS-O
57
More Rapid Opioid Taper: 20% /4 days
0100200300400500600700800900
1,000
1 9 17 25 33 41 49 57 65 73 81
57DAY
Mg/
d
58
EMERGENCY no taper
1. Altering a prescription = FELONY2. Selling Rx or drugs = DRUG DEALING3. Accidental/intentional overdose = DEATH?4. Threatening staff = EXTORTION5. Too many stories = OUT OF CONTROL
2015 PCSS-O
59
SUMMARY• Naloxone has a very important place• Chronic OPIOIDs not safe or effective -
Ballantyne• 18-20 Years of opioids based on studies that
lasted < 6 wks (chronic pain is >12 wks)• OPIOID MI risk higher than COX-2 • After FISHMAN’s book ROP the deaths
increased; Provider Ed isn’t enough• VA study opiate vs. nonopiate = no difference
2015 PCSS-O
60
SUMMARY• Poor outcomes – LBP, fibromyalgia & headache• 5 reasons to discontinue• 3 phases of weaning • 4 options at high dose• 10 WEEK TAPER• EMERGENCY – no taper• REMS may not be bold enough to impact “The Problem”• Knowing “Discontinuation” is more important than
cautious dose increase when goals are not met.
2015 PCSS-O
61
THE END
2015 PCSS-O
62
References
• NIH 9/28-29/2014 Pathways to Prevention: Opioids • Ballantyne et al 2003 NEJM• Chou et al 2009 Pain• Katz et al 2007 PainEDU.org• Hill et al 2011 Lancet• Carman et al 2011 Pharmacoepidem & Drug Safety• Osterwell 2013 Medscape.com/viewarticle/814200#vp_1• http://wonder.cdc.gov• http://www.dea.gov• Holm et al 2012 AP analysis of DEA data• Walley et al 2013 BMJ• CO*RE-REMS
63
PCSS-O Colleague Support Program
• PCSS-O Colleague Support Program is designed to offer general information to health professionals seeking guidance in their clinical practice in prescribing opioid medications.
• PCSS-O Mentors comprise a national network of trained providers with expertise in addiction medicine/psychiatry and pain management.
• Our mentoring approach allows every mentor/mentee relationship to be unique and catered to the specific needs of both parties.
• The mentoring program is available at no cost to providers.
• Listserv: A resource that provides an “Expert of the Month” who will answer questions about educational content that has been presented through PCSS-O project. To join email: [email protected].
For more information on requesting or becoming a mentor visit:www.pcss-o.org/colleague-support
64
PCSS-O is a collaborative effort led by American Academy of Addiction Psychiatry (AAAP) in partnership with: Addiction Technology Transfer Center (ATTC), American Academy of Neurology (AAN), American Academy of Pain Medicine (AAPM), American Academy of Pediatrics (AAP), American College of Physicians (ACP), American Dental
Association (ADA), American Medical Association (AMA), American Osteopathic Academy of Addiction Medicine (AOAAM), American Psychiatric Association (APA),
American Society for Pain Management Nursing (ASPMN), International Nurses Society on Addictions (IntNSA), and Southeast Consortium for Substance Abuse Training
(SECSAT).
For more information visit: www.pcss-o.orgFor questions email: [email protected]
Twitter: @PCSSProjects
Funding for this initiative was made possible (in part) by Providers’ Clinical Support System for Opioid Therapies (grant no. 1H79TI025595) from SAMHSA. The views expressed in written conference materials or publications and by speakers and
moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.